Found 460 results in Expert Content

Summary: Download this executive summary to learn more about safe and successful HPAPI product development and manufacturing using micronization.

Summary: As drug developers look to address unmet medical needs for orphan diseases, working with experienced partners can help in navigating key challenges such as a limited active pharmaceutical ingredient supply, efficient small-scale manufacturing for small patient populations and distribution logistics

Summary: To rapidly screen macromolecules’ potential for oral delivery, it is critical to assess multiple enabling technologies in parallel, targeting different biological barriers.

Summary: Decisions made throughout early and mid-stage clinical trials impact late-stage results and sometimes, entire programs and companies. Since some obstacles can prove overwhelming for startups, there is a lot to learn from those who successfully walked the path.

Read this case study to learn about how Catalent deployed its integrated OneXpress® Solution to expedite the transfer of a partner program to one of its late-stage manufacturing sites while optimizing the utilization of a limited supply of API.

Summary: During Fierce JPM Week 2022, Catalent’s President and COO Alessandro Maselli sat down and discussed how the pandemic changed the pharmaceutical landscape and how CDMOs...

Summary: In this webinar, experts provide an overview of the needs of different patient populations and examine the common challenges leading to non-compliance.

Summary: Catalent’s CEO John Chiminski and Endpoints News’ John Carroll have a virtual fireside chat discussing their predictions for what 2022 has in store for the biopharma industry.

Learn how a biopharmaceutical company partnered with Catalent to develop and manufacture a commercially-viable, patient-friendly, stable tablet for a program intended to treat a disease that has unmet medical need.

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.